TP53 and cancer: In a recent manuscript in “Clinical Cancer Research”, we utilized an extremes-of-survivorship approach in patients with resected colorectal cancer liver metastasis (CRLM) and demonstrated that concurrent mutations in both Ras pathway and TP53 alterations were significantly more frequent in ≤ 2-year survivors, whereas co-altered Ras-TP53 was absent in ≥ 10-year survivors (67% vs. 0%, P < 0.001) [3].